Connor Clark & Lunn Investment Management Ltd. Buys Shares of 59,970 Lifevantage Corporation $LFVN

Connor Clark & Lunn Investment Management Ltd. purchased a new position in Lifevantage Corporation (NASDAQ:LFVNFree Report) in the second quarter, Holdings Channel.com reports. The firm purchased 59,970 shares of the company’s stock, valued at approximately $784,000.

Several other hedge funds have also recently made changes to their positions in LFVN. Los Angeles Capital Management LLC purchased a new stake in Lifevantage in the second quarter worth approximately $288,000. AlphaQuest LLC lifted its holdings in shares of Lifevantage by 12,659.7% during the 2nd quarter. AlphaQuest LLC now owns 7,911 shares of the company’s stock valued at $103,000 after buying an additional 7,849 shares during the period. Capital Management Corp VA boosted its stake in shares of Lifevantage by 77.0% in the 2nd quarter. Capital Management Corp VA now owns 1,266,110 shares of the company’s stock worth $16,561,000 after buying an additional 550,607 shares during the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Lifevantage in the second quarter worth $25,000. Finally, Goldman Sachs Group Inc. increased its position in Lifevantage by 24.5% during the first quarter. Goldman Sachs Group Inc. now owns 44,518 shares of the company’s stock valued at $649,000 after acquiring an additional 8,762 shares during the last quarter. 35.32% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Lifevantage

In other Lifevantage news, Director Michael A. Beindorff sold 35,000 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $6.92, for a total value of $242,200.00. Following the completion of the sale, the director owned 56,413 shares in the company, valued at approximately $390,377.96. This represents a 38.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 40,325 shares of company stock valued at $298,990. Corporate insiders own 21.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LFVN. Wall Street Zen cut Lifevantage from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Lifevantage in a report on Monday. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Lifevantage in a report on Wednesday, November 5th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.50.

Get Our Latest Stock Analysis on LFVN

Lifevantage Trading Up 3.0%

Shares of NASDAQ:LFVN opened at $6.48 on Wednesday. The stock has a 50 day moving average of $8.91 and a 200 day moving average of $11.47. The company has a market cap of $82.30 million, a PE ratio of 8.76 and a beta of 0.22. Lifevantage Corporation has a 12-month low of $5.98 and a 12-month high of $27.38.

Lifevantage (NASDAQ:LFVNGet Free Report) last released its earnings results on Tuesday, November 4th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.01. The company had revenue of $47.56 million for the quarter, compared to analysts’ expectations of $54.74 million. Lifevantage had a net margin of 4.29% and a return on equity of 33.75%. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Lifevantage Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Investors of record on Monday, December 1st will be issued a $0.045 dividend. The ex-dividend date of this dividend is Monday, December 1st. This represents a $0.18 annualized dividend and a yield of 2.8%. Lifevantage’s dividend payout ratio is currently 23.38%.

Lifevantage Profile

(Free Report)

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

Further Reading

Want to see what other hedge funds are holding LFVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lifevantage Corporation (NASDAQ:LFVNFree Report).

Institutional Ownership by Quarter for Lifevantage (NASDAQ:LFVN)

Receive News & Ratings for Lifevantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifevantage and related companies with MarketBeat.com's FREE daily email newsletter.